Tendersinfo Gulf

Filter Search

Europe

Location Summary Deadline
Germany Openhousevergabe 20244 2026-11-30
Germany Abschluss Nicht Exklusiver Rabattverträge Gemäß §§ 130a Abs. 8/130c Abs. 1 Sgb V Zu Arzneimitteln Mit Dem Wirkstoff Dornase Alfa (r05cb13) Im Rahmen Eines Sogenannten Open-house-modells. 2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Section 130a Paragraph 8/130c Paragraph 1 Social Security Code V For Medicinal Products Containing The Active Ingredient Acetylsalicylic Acid (b01ac06) Within The Framework Of A So-called Open Ho 2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Sections 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Nilotinib (l01ea03), Without Administration Dispersed In Apple Sauce (pureed Apple) Within 2026-11-30
Germany Conclusion Not Excluding Drug Discount Agreement According To § 130a Para. 8 Sgb V By Means Of An Open House Model For The Active Ingredient Etanercept (atc Code According To Who 2026-11-30
Germany Medicines Containing The Active Ingredient Mesalazine (atc 2026-11-30
Germany Conclusion Of A Non-exclusive Drug Discount Agreement Pursuant To Section 130a Paragraph 8 Of The Social Code Book V By Means Of An Open-house Model For The Active Ingredient Adalimumab (atc Code According To Who: L04ab04) 2026-11-30
Germany Medicines Containing The Active Ingredient Epinephrine (atc: C01ca24) 2026-11-30
Germany Medicines Containing The Active Ingredient Pyridostigmine (atc: N07aa02) 2026-11-30
Germany Conclusion Of Non-exclusive Discount Agreements Pursuant To Sections 130a Paragraph 8/130c Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Peginterferon Beta1a (l03ab13) Within The Framework Of A So-called Open House Model. 2026-11-30
Whats app